Cardiovascular progenitor–derived extracellular vesicles recapitulate the beneficial effects of their parent cells in the treatment of chronic heart failure
A Kervadec, V Bellamy, N El Harane… - The Journal of Heart and …, 2016 - Elsevier
Background Cell-based therapies are being explored as a therapeutic option for patients
with chronic heart failure following myocardial infarction. Extracellular vesicles (EV),
including exosomes and microparticles, secreted by transplanted cells may orchestrate their
paracrine therapeutic effects. We assessed whether post-infarction administration of EV
released by human embryonic stem cell–derived cardiovascular progenitors (hESC-Pg) can
provide equivalent benefits to administered hESC-Pg and whether hESC-Pg and EV …
with chronic heart failure following myocardial infarction. Extracellular vesicles (EV),
including exosomes and microparticles, secreted by transplanted cells may orchestrate their
paracrine therapeutic effects. We assessed whether post-infarction administration of EV
released by human embryonic stem cell–derived cardiovascular progenitors (hESC-Pg) can
provide equivalent benefits to administered hESC-Pg and whether hESC-Pg and EV …